Barrett’s Oesophagus: What It Means & What Happens Next

What the diagnosis actually means, the cancer risk in honest proportion, how UK surveillance works, and why long-term PPIs are recommended.

Part of the Complete Acid Reflux Guide.

What Barrett’s oesophagus is

The oesophagus is lined with flat, skin-like cells built for passing food — not for withstanding acid. After years of reflux, the lower oesophagus can respond by changing its lining: the flat cells are replaced by column-shaped cells more like those of the intestine, which tolerate acid better. This adaptation is Barrett’s oesophagus.

In one sense it is a sensible repair — the new lining burns less, which is why some people’s heartburn actually eases as Barrett’s develops. The catch is that the changed cells are less stable than the originals, and over many years a small minority can drift through precancerous steps (dysplasia) towards oesophageal adenocarcinoma. That two-sided character — mostly harmless adaptation, occasionally the first step on a longer road — is why Barrett’s is taken seriously without being treated as an emergency.

How it’s found

Barrett’s produces no symptoms of its own — it is found by endoscopy, usually arranged for long-standing reflux, and confirmed by biopsies. The endoscopist sees a salmon-pink tongue of changed lining extending up from the stomach junction and records its length (you may see “C” and “M” measurements — the Prague classification — on your report). It is more common in men, in people over 50, with long-standing reflux, obesity or a family history. Around 1 in 10 people having endoscopy for chronic reflux are found to have it.

The cancer question, answered honestly

This is the question every newly diagnosed person carries out of clinic, so here it is directly. Most people with Barrett’s never develop oesophageal cancer. For Barrett’s without dysplasia, large studies put progression at around 0.3% per year or lower — put another way, well over 95% of people with uncomplicated Barrett’s will never progress. The risk is real enough to justify monitoring, and small enough that it should not dominate your life.

The reason surveillance still matters: when the rare progression does begin, it moves through visible, biopsy-detectable stages — low-grade dysplasia, high-grade dysplasia — over years. Caught at those stages, endoscopic treatment is highly effective and cancer is usually prevented entirely. Surveillance converts a small unpredictable risk into a managed one.

Surveillance: what to expect in the UK

UK practice follows British Society of Gastroenterology guidance. For Barrett’s without dysplasia, a repeat endoscopy with biopsies every 3–5 years — longer segments towards the 3-year end, short segments towards 5, and for very short segments your specialist may discuss whether surveillance is needed at all. If biopsies show low-grade dysplasia, follow-up tightens to around 6 months and endoscopic treatment is often offered; high-grade dysplasia means prompt referral to a specialist centre for treatment rather than watching. Between endoscopies, no scans or blood tests are needed — just your PPI and a low threshold for reporting new swallowing symptoms.

Treatment: why long-term PPIs are recommended

Daily PPI treatment — typically omeprazole or esomeprazole — is recommended for most people with Barrett’s, indefinitely. The logic is twofold: it controls the reflux that created the condition, and trial evidence (notably the AspECT study) suggests acid suppression reduces the risk of progression. Barrett’s is therefore one of the clearest cases where long-term PPI use is the right call — if you read about PPI risks, weigh them against this specific benefit, and do not stop or step down without specialist advice. Our guide to stopping PPIs lists Barrett’s prominently among the do-not-stop conditions.

Lifestyle work still counts: weight loss, not smoking, moderating alcohol and the standard reflux measures all reduce ongoing acid exposure — see foods to avoid and the night-time reflux guide.

If dysplasia develops: ablation and EMR

Should biopsies ever show dysplasia, treatment has been transformed over the past two decades. Radiofrequency ablation (RFA) uses controlled heat, delivered through the endoscope, to remove the Barrett’s lining so normal cells regrow; endoscopic mucosal resection (EMR) lifts and removes any raised or nodular areas. Both are outpatient endoscopic procedures — not open surgery — with success rates above 90% for eradicating dysplasia. The era when Barrett’s complications meant major surgery is largely over, provided changes are caught by surveillance.

Living with Barrett’s

Between endoscopies, Barrett’s asks little of you: take the PPI daily, keep the lifestyle measures going, attend surveillance when called. The symptoms that should prompt review without waiting for the next endoscopy: food sticking or pain when swallowing, unintentional weight loss, vomiting blood, or black tarry stools.

Ongoing treatment from Access Doctor

Access Doctor’s pharmacist independent prescribers can keep the long-term PPI treatment that Barrett’s requires reviewed and supplied, following a short online consultation with discreet UK delivery.